Figure 4:
Summary of the overall approach to glucose-lowering medications in type 2 diabetes as recommended by the 2018 consensus report of the American Diabetes Association and European Association for the Study of Diabetes.34 Note: ASCVD = atherosclerotic cardiovascular disease, CKD = chronic kidney disease, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, GLP-1 = glucagon-like peptide-1, HbA1c = glycated hemoglobin, SGLT2 = sodium-glucose cotransporter-2.